Immunitybio Inc
$ 11.55
17.50%
24 Feb - close price
- Market Cap 11,376,348,000 USD
- Current Price $ 11.55
- High / Low $ 12.28 / 9.95
- Stock P/E N/A
- Book Value -0.53
- EPS -0.41
- Next Earning Report 2026-03-02
- Dividend Per Share N/A
- Dividend Yield 0 %
- Next Dividend Date -
- ROA -0.37 %
- ROE N/A %
- 52 Week High 12.28
- 52 Week Low 1.83
About
ImmunityBio, Inc., an immunotherapy company, develops a memory T-cell cancer vaccine to fight multiple types of tumors without the use of high-dose chemotherapy.
Analyst Target Price
$12.60
Quarterly Earnings
| Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Dec 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported Date | 2025-11-05 | 2025-08-05 | 2025-05-07 | 2025-03-17 | 2024-11-06 | 2024-08-06 | 2024-05-09 | 2024-03-19 | 2023-11-09 | 2023-08-08 | 2023-05-11 | 2023-03-01 |
| Reported EPS | -0.07 | -0.1 | -0.15 | -0.08 | -0.1232 | -0.2 | -0.2 | -0.35 | -0.19 | -0.32 | -0.27 | -0.27 |
| Estimated EPS | -0.11 | -0.11 | -0.16 | -0.13 | -0.18 | -0.17 | -0.16 | -0.18 | -0.25 | -0.23 | -0.27 | -0.22 |
| Surprise | 0.04 | 0.01 | 0.01 | 0.05 | 0.0568 | -0.03 | -0.04 | -0.17 | 0.06 | -0.09 | 0 | -0.05 |
| Surprise Percentage | 36.3636% | 9.0909% | 6.25% | 38.4615% | 31.5556% | -17.6471% | -25% | -94.4444% | 24% | -39.1304% | 0% | -22.7273% |
Next Quarterly Earnings
| Dec 2025 | |
|---|---|
| Reported Date | 2026-03-02 |
| Fiscal Date Ending | 2025-12-31 |
| Estimated EPS | -0.08 |
| Currency | USD |
Next Dividend Records
| Dividend per share (year): | - |
| Dividend Yield | - |
| Next Dividend Date | - |
| Ex-Dividend Date | - |
Recent News: IBRX
2026-02-24 16:52:14
ImmunityBio's ANKTIVA received conditional marketing approval in the EU, expanding its reach to 33 countries. This regulatory win and strategic partnerships, like the one with Accord Healthcare, have significantly boosted ImmunityBio's stock by 14.5% despite ongoing financial challenges and ambitious global expansion plans. The company reported a substantial revenue increase of 700% in 2025 due to ANKTIVA's global rollout, but still faces profitability hurdles and high R&D spending.
2026-02-23 20:59:20
ImmunityBio's Founder, Dr. Patrick Soon-Shiong, will speak at the "Cancer 2035: A Roadmap for the Future" summit co-hosted by the Milken Institute and the Richard Nixon Foundation in Washington, D.C. The summit, held on February 23–24, 2026, will gather leaders in oncology, immunology, and health policy to discuss strategies for significantly reducing cancer mortality by 2035, coinciding with the 55th anniversary of the National Cancer Act. This event highlights ImmunityBio's pioneering work in immunotherapy and Dr. Soon-Shiong's dedication to cancer treatment.
2026-02-23 20:59:20
ImmunityBio, Inc. announced that its founder, Dr. Patrick Soon-Shiong, will be a featured speaker at the "Cancer 2035: A Roadmap for the Future" summit. Co-hosted by the Milken Institute and the Richard Nixon Foundation, the event gathers leaders in oncology, immunology, and health policy to strategize on significantly reducing cancer mortality by 2035, coinciding with the 55th anniversary of the National Cancer Act. Dr. Soon-Shiong will join Nobel laureates and former NIH directors to discuss the future of cancer research and treatment.
2026-02-23 17:54:35
ImmunityBio Inc. (NASDAQ: IBRX) shares surged following the announcement of a remarkable 700% year-over-year revenue increase, propelled by strong sales of its bladder cancer drug, Anktiva. The company's fourth-quarter revenue significantly beat analyst expectations, and positive technical indicators alongside strategic initiatives contributed to the stock nearing its 52-week high.
2026-02-23 15:54:35
ImmunityBio announced significant financial and operational results for 2025, including a 700% year-over-year revenue growth for its ANKTIVA product, reaching $113 million. The company also secured global regulatory approvals for ANKTIVA in bladder cancer across 33 countries and received its first approval for lung cancer in Saudi Arabia, with plans for further label expansion and global commercial partnerships. ImmunityBio emphasizes ANKTIVA's role as a backbone in its Cancer BioShield platform, supported by ongoing clinical trials and long-term patent protection.
2026-02-23 12:49:35
ImmunityBio (IBRX) saw its stock gain 1% in pre-market trading after reporting better-than-expected fourth-quarter results. The company's net product revenue surged 431% to $38.3 million, surpassing estimates, largely due to strong sales of ANKTIVA, an FDA-approved immunotherapy. Despite the revenue boost, Q4 net loss widened to $61.9 million due to increased R&D expenses.
